Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for LAURUSLABS
Revenue projections for LAURUSLABS

Revenues for LAURUSLABS are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 1.328000
forwardPE 56.761845
debtToEquity 46.369000
earningsGrowth 0.194000
revenueGrowth 0.053000
grossMargins 0.604360
operatingMargins 0.215290
trailingEps 15.600000
forwardEps 24.204640

With a current ratio 1.328, Laurus Labs Limited demonstrates the ability to service its short-term debt without difficulty. The company's strong cash reserves and current assets ensure that it can meet its liabilities, reflecting financial stability and healthy liquidity.
LAURUSLABS's elevated forward PE ratio suggests limited upside potential and a risk of price correction. Investors must scrutinize this metric closely, ensuring it aligns with other fundamental indicators before making any decisions.
LAURUSLABS's positive gross and operating margins reflect its profitability and efficiency. These metrics demonstrate the company's ability to manage costs effectively while generating strong revenue, highlighting its solid financial health and operational effectiveness.
With Laurus Labs Limited's forward EPS higher than its trailing EPS, the company is expected to be more profitable in the current financial year. This signals confidence in Laurus Labs Limited's growth potential, as improved earnings are forecasted compared to the prior year's performance.

Price projections:

Price projections for LAURUSLABS
Price projections for LAURUSLABS

With LAURUSLABS's price exceeding the higher end of projections, it reflects a strong upward trend. Yet, the limited potential for additional increases may mean that the stock is nearing its peak, prompting investors to evaluate their positions.

Recommendation changes over time:

Recommendations trend for LAURUSLABS
Recommendations trend for LAURUSLABS


A recent buy bias from analysts toward LAURUSLABS indicates strong confidence in the stock's future performance. This could encourage investors to park their money in LAURUSLABS, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.